世界の遺伝子編集の提携条件と契約（2016年～2023年）

当レポートでは、世界の遺伝子編集の提携条件と契約について調査し、2010年以降に発表された遺伝子編集関連の提携取引をリストアップし、可能な限り財務条件も含めて、取引当事者が開示した実際の取引に関するオンライン記録へのリンクを400件以上掲載しています。さらに、入手可能な場合には、証券取引委員会に提出した契約文書も記載しています。

目次

エグゼクティブサマリー

第1章 イントロダクション

第2章 遺伝子編集ディールメイキングの動向

• イントロダクション
• 長年にわたる遺伝子編集の提携
• 最も活動している遺伝子編集の取引メーカー
• 取引タイプ別：遺伝子編集提携
• 治療領域別の遺伝子編集提携
• 遺伝子編集提携の取引条件
  • 遺伝子編集提携の見出しの値
  • 遺伝子編集取引の前払い
  • 遺伝子編集取引のマイルストーン支払い
  • 遺伝子編集使用料率

第3章 主な遺伝子編集の取引

• イントロダクション
• 金額別：遺伝子編集の主要取引

第4章 遺伝子編集の取引で最も活動しているメーカー

• イントロダクション
• 最も活動しているメーカー
• 最も活動している提携企業のプロファイル

第5章 遺伝子編集契約の取引ディレクトリ

• イントロダクション
• 遺伝子編集契約の取引ディレクトリ

第6章 技術タイプ別：遺伝子編集取引

付録

• 付録1 - A～Z企業別：遺伝子編集の取引
• 付録2 - 開発段階別：遺伝子編集の取引
• 付録3 - 取引タイプ別：遺伝子編集の取引
• 付録4 - 治療分野別：遺伝子編集の取引
• 付録5 - 取引タイプの定義

Wildwood Venturesについて

Description

Gene Editing Collaboration and Licensing Deals provides a comprehensive understanding and unprecedented access to the gene editing deals entered into by the worlds leading biopharma companies.

Fully revised and updated, the report provides details of gene editing deals from 2016 to 2023.

The report provides a detailed understanding and analysis of how and why companies enter gene editing deals. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

The report includes collaboration, development, research and licensing deals.

This report contains a comprehensive listing of 333 gene editing deals announced since 2016 including financial terms where available including links to online deal records of actual gene editing partnering deals as disclosed by the deal parties. In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners.

The initial chapters of this report provide an orientation of gene editing dealmaking.

Chapter 1 provides an introduction to the report.

Chapter 2 provides an overview of the trends in gene editing dealmaking since 2016.

Chapter 3 provides an overview of the leading gene editing deals since 2016. Deals are listed by headline value.

Chapter 4 provides a comprehensive listing of the top 25 most active companies in gene editing dealmaking with a brief summary followed by a comprehensive listing of gene editing deals, as well as contract documents available in the public domain.

Chapter 5 provides a comprehensive and detailed review of gene editing deals signed and announced since Jan 2016, where a contract document is available in the public domain.

Chapter 6 provides a comprehensive and detailed review of gene editing partnering deals signed and announced since Jan 2016. The chapter is organized by specific gene editing technology type in focus.

The report also includes numerous table and figures that illustrate the trends and activities in gene editing deal making since 2016.

In addition, a comprehensive deal directory is provided organized by company A-Z, deal type and therapeutic target. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

Key benefits

Gene Editing Collaboration and Licensing Deals provides the reader with the following key benefits:

• Understand deal trends since 2016
• Browse gene editing collaboration and licensing deals
• Benchmark analysis - identify market value of transactions
• Financials terms - upfront, milestone, royalties
• Directory of deals by company A-Z, deal type and therapy area
• Leading deals by value
• Most active dealmakers
• Identify assets and deal terms for each transaction
• Access contract documents - insights into deal structures
• Due diligence - assess suitability of your proposed deal terms for partner companies
• Save hundreds of hours of research time

Report scope

• Gene Editing Collaboration and Licensing Deals is intended to provide the reader with an in-depth understanding of gene editing trends and structure of deals entered into by leading biopharma companies worldwide.

Gene Editing Collaboration and Licensing Deals includes:

• Trends in gene editing dealmaking in the biopharma industry
• Directory of gene editing deal records covering pharmaceutical and biotechnology
• The leading gene editing deals by value
• Most active gene editing licensing dealmakers
• Gene Editing Collaboration and Licensing Deals provides comprehensive access to available records for deals, including contract documents where available.

Analyzing contract agreements allows due diligence of:

• What are the precise rights granted or optioned?
• What is actually granted by the agreement to the partner company?
• What exclusivity is granted?
• What is the payment structure for the deal?
• How are sales and payments audited?
• What is the deal term?
• How are the key terms of the agreement defined?
• How are IPRs handled and owned?
• Who is responsible for commercialization?
• Who is responsible for development, supply, and manufacture?
• How is confidentiality and publication managed?
• How are disputes to be resolved?
• Under what conditions can the deal be terminated?
• What happens when there is a change of ownership?
• What sublicensing and subcontracting provisions have been agreed?
• Which boilerplate clauses does the company insist upon?
• Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
• Which jurisdiction does the company insist upon for agreement law?

Benefits

Gene Editing Collaboration and Licensing Deals provides the reader with the following key benefits:

• Understand deal trends since 2016
• Browse gene editing collaboration and licensing deals
• Benchmark analysis - identify market value of transactions
• Financials terms - upfront, milestone, royalties
• Directory of deals by company A-Z, deal type and therapy area
• Leading deals by value
• Most active dealmakers
• Identify assets and deal terms for each transaction
• Access contract documents - insights into deal structures
• Due diligence - assess suitability of your proposed deal terms for partner companies
• Save hundreds of hours of research time

Table of Contents

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in gene editing dealmaking

• 2.1. Introduction
• 2.2. Gene editing deals over the years
• 2.3. Most active gene editing dealmakers
• 2.4. Gene editing deals by deal type
• 2.5. Gene editing deals by therapy area
• 2.6. Gene editing deals by industry sector
• 2.7. Deal terms for gene editing deals
  • 2.7.1 Gene editing deals headline values
  • 2.7.2 Gene editing deal upfront payments
  • 2.7.3 Gene editing deal milestone payments
  • 2.7.4 Gene editing royalty rates

Chapter 3 - Leading gene editing deals

• 3.1. Introduction
• 3.2. Top gene editing deals by value

Chapter 4 - Most active gene editing dealmakers

• 4.1. Introduction
• 4.2. Most active gene editing dealmakers
• 4.3. Most active gene editing deals company profiles

Chapter 5 - Gene editing contracts dealmaking directory

• 5.1. Introduction
• 5.2. Gene editing contracts dealmaking directory

Chapter 6 - Gene editing dealmaking by technology type

• Deal directory
• Deal directory - Gene editing deals by company A-Z
• Deal directory - Gene editing deals by deal type
• Deal directory - Gene editing deals by therapy area
• Deal type definitions
• About Wildwood Ventures
• Current Partnering
• Current Agreements
• Recent report titles from Current Partnering
•  

Table of figures

• Figure 1: Gene editing deals since 2016
• Figure 2: Active gene editing dealmaking activity - 2016 - 2023
• Figure 3: Gene editing deals by deal type since 2016
• Figure 4: Gene editing deals by therapy area since 2016
• Figure 5: Gene editing deals by industry sector since 2016
• Figure 6: Gene editing deals with a headline value
• Figure 7: Gene editing deals with an upfront value
• Figure 8: Gene editing deals with a milestone value
• Figure 9: Gene editing deals with a royalty rate value
• Figure 10: Top gene editing deals by value since 2016
• Figure 11: Most active gene editing dealmakers 2016 - 2023
• Figure 12: Gene editing deals by technology type since 2016